US Capital Global Securities Launches $10MM Convertible Preferred Stock Offering for Cardax, Inc.
24 nov. 2020 16h58 HE
|
US Capital Global
San Francisco, California, Nov. 24, 2020 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, is offering to eligible investors an investment opportunity of up to...
Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001
18 nov. 2020 09h00 HE
|
Enosi Life Sciences
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enosi Life Sciences Corp. (“Enosi” or the “Company”), a drug research and development company focused on providing industry-leading therapeutics for...
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
17 nov. 2020 08h00 HE
|
180 Life Sciences Corp.
MENLO PARK, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused...
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
15 nov. 2020 19h35 HE
|
BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Groundbreaking Studies Offer Hope for Unmet Medical Needs in Inflammatory Disease
01 oct. 2020 08h30 HE
|
180 Life Sciences Corp.
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- 180 Life Sciences Corp. (NASDAQ: KBLM) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
03 sept. 2020 21h42 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
Therapeutic Antibody Pioneers Professor Sir Marc Feldmann and Dr. H. Michael Shepard Formally Launch Enosi Life Sciences
02 sept. 2020 09h00 HE
|
Enosi Life Sciences
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- World-renowned scientists Professor Sir Marc Feldmann and Dr. H. Michael Shepard are pleased to announce the formal launch of Enosi Life Sciences...
Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity
17 août 2020 10h57 HE
|
BioAegis Therapeutics
BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic MORRISTOWN, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing...
BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
05 août 2020 18h16 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
15 juil. 2020 13h34 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...